TLDR
- Immutep shares plummeted approximately 80% Friday following discontinuation of its Phase III lung cancer study due to futility findings.
- The Independent Data Monitoring Committee advised terminating the TACTI-004 trial examining eftilagimod alfa (efti) for first-line non-small cell lung cancer treatment.
- Baird revised its rating from Outperform to Neutral while reducing the price target from $7.00 down to $1.00.
- Citizens lowered its rating from Market Outperform to Market Perform while eliminating all NSCLC-related revenue forecasts.
- Share volume surged past 11 million — dramatically higher than the typical daily average near 154,000 — reflecting massive investor selloff.
Immutep (IMMP) experienced an approximately 80% decline Friday following the company’s announcement regarding its TACTI-004 Phase III clinical trial discontinuation. The trial had been assessing eftilagimod alfa, referred to as “efti,” for treating patients with first-line non-small cell lung cancer (NSCLC).
The termination followed guidance from the Independent Data Monitoring Committee (IDMC), which assessed both safety and efficacy information and determined the trial warranted cessation due to futility. Translation: the available data indicated the therapy would likely fail to achieve its primary endpoints even with continued execution.
CEO Marc Voigt expressed clear dissatisfaction with the outcome. “We are very disappointed and surprised with the outcome of the futility analysis, in light of efti’s performance in every other clinical trial,” he stated in the company’s announcement.
Immutep confirmed it will immediately cease new patient enrollment and commence systematic trial closure, encompassing patient monitoring and site shutdowns according to regulatory standards.
Wall Street Analysts Revise Positions and Targets
The investment community responded immediately — matching the speed of the market selloff.
Baird analyst Colleen Kusy revised IMMP from Outperform to Neutral while lowering her price objective from $7.00 to $1.00. Shares were trading near $2.76 when the downgrade occurred, placing them significantly above the newly established target. Baird indicated the firm cannot identify a viable development pathway for efti given these results.
Citizens analyst Reni Benjamin similarly revised the stock rating, shifting from Market Outperform to Market Perform. Benjamin eliminated all revenue estimates connected to the NSCLC indication from the financial model.
Both analysts anticipate the stock will track alongside broader market performance until substantial data emerges from other randomized trials in progress.
IMMP shares had declined roughly 3.5% year-to-date prior to Friday’s announcement, though they had climbed 55% during the preceding 12-month period. That previous gain has now been essentially eliminated.
What Lies Ahead for Immutep
The company identified one positive outcome: terminating the TACTI-004 trial removes its associated expenses. Immutep now anticipates its available cash will last substantially longer than the previously communicated Q2 2027 projection. The company plans to provide a revised cash forecast after completing trial shutdown procedures.
Immutep confirmed it will maintain focus on additional pipeline programs. The NSCLC program represented the lead development asset, meaning the company’s strategic options now appear significantly more limited.
Friday’s trading activity illustrated the severity of investor reaction. Over 11 million shares traded during the morning session alone — a stark contrast to the three-month average daily volume hovering around 154,000. That represents approximately 70 times typical trading activity.
The consensus rating on IMMP currently stands at Hold, reflecting two Hold ratings. No average price target exists for the stock at present.
